Fig. 3From: Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trialTime-course of bronchodilator activity of FF/VI. a: FEV1 change from baseline. b: PEF. Mean (a) FEV1 (L) after cessation of treatment and (b) Peak expiratory flow (L/min), during treatment and after cessation of treatment, plotted over time, for placebo (grey line) and FF/VI (black line). Error bars denote the standard errorBack to article page